Amgen’s Ian Thompson On Payer Shifts, Obesity Opportunity And The Future Of Blockbusters
Launches Have Longer Ramp-Up In High-Pressure Markets
Executive Summary
Scrip spoke with Amgen’s senior VP of US business operations about the impact of drug pricing and reimbursement pressures coming from government policy changes and commercial payers.